Lyka Labs Q4 FY26 Results: Loss Rs 8.07 Cr

Lyka Labs Q4 FY26 results were declared on May 25, 2026. The company reported net loss of Rs 8.07 crore for the quarter ended March 31, 2026, down 497.5% YoY compared to Rs 2.03 crore in Q4 FY25. Revenue from operations was Rs 28.03 crore, down 16.2% YoY. Results are on a Consolidated basis. Lyka Labs is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Lyka Labs Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 28.03 crore	Rs 33.43 crore	-16.2%
Net Loss	8.07	2.03	-497.5%
Basis	Consolidated

Note: Lyka Labs Q4 FY26 results declared May 25, 2026. Data sourced from Screener.in BSE filings. Verify from audited statements before investment decisions.

Lyka Labs Q4 FY26 Performance Analysis

The Lyka Labs Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter shows near-term profitability challenges. Lyka Labs operates in the Pharmaceuticals sector, supported by India’s GDP growth above 6.5% and domestic demand conditions in FY26.

Revenue of Rs 28.03 crore was down 16.2% YoY. Revenue moderation reflects near-term demand headwinds.

Screen the best stocks on the Univest Screener.

Key Factors Driving Lyka Labs Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 28.03 crore in Lyka Labs Q4 FY26 was down 16.2% YoY. Revenue pressure reflects near-term demand headwinds in the Pharmaceuticals market. The January to March quarter is the fiscal year-end period characterised by strong execution cycles and year-end activity across Indian companies.

Profitability and Margin Trends

The the business net loss of Rs 8.07 crore down 497.5% YoY. Net loss reflects ongoing operational challenges with FY27 recovery as management’s focus.

India Macro Environment Q4 FY26

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Reserve Bank of India’s accommodative stance supported credit conditions. The Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement roadmap, and capital allocation priorities will be key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s long-term structural growth story. Returning to profitability through operational improvements remains the key FY27 objective.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.